Table 2.
Selected patient and tumor characteristics (N = 826)
| Parameters | N (%) |
|---|---|
| Age (y) | |
| N | 826 |
| Mean (SD) | 53.0 (11.3) |
| Median (min‐max) | 52.7 (22‐79) |
| Age (median cutoff) | |
| ≤52.7 | 415 (50.2%) |
| >52.7 | 411 (49.8%) |
| Menopausal status | |
| Postmenopausal | 448 (54.2%) |
| Premenopausal | 378 (45.8%) |
| Breast surgery | |
| Breast‐conserving surgery | 242 (29.3%) |
| Modified radical mastectomy | 583 (70.6%) |
| Not reported | 1 (0.1%) |
| Tumor size (cm) | |
| ≤2 | 252 (30.5%) |
| 2‐5 | 472 (57.1%) |
| >5 | 102 (12.3%) |
| Positive lymph nodes | |
| 0‐3 | 335 (40.6%) |
| ≥4 | 491 (59.4%) |
| Treatment group | |
| E‐CMF | 141 (17.1%) |
| E‐T‐CMF | 396 (47.9%) |
| ET‐CMF | 289 (35.0%) |
| Adjuvant hormonal therapy | |
| No | 150 (18.2%) |
| Yes | 660 (79.9%) |
| Not reported | 16 (1.9%) |
| Adjuvant radiotherapy | |
| No | 181 (21.9%) |
| Yes | 624 (75.5%) |
| Not reported | 21 (2.5%) |
| Histological grade | |
| I‐II | 409 (49.5%) |
| III‐IV | 416 (50.4%) |
| Not reported | 1 (0.1%) |
| TNM stage | |
| IA | 4 (0.5%) |
| IIA | 113 (13.7%) |
| IIB | 189 (22.9%) |
| IIIA | 340 (41.2%) |
| IIIC | 180 (21.8%) |
| ER/PgR status | |
| Informative N (%) | 770 (93.2%) |
| Positive | 608 (79.0%) |
| Negative | 162 (21.0%) |
| HER2 status | |
| Informative N (%) | 778 (94.2%) |
| Positive | 184 (23.7%) |
| Negative | 594 (76.3%) |
| Ki67 | |
| Informative N (%) | 767 (92.9%) |
| Mean (SD) | 31.4 (24.3) |
| Median (min‐max) | 25 (0‐98) |
| TILs | |
| Informative N (%) | 786 (95.2%) |
| Mean (SD) | 12.6 (14.8) |
| Median (min‐max) | 8 (0‐90) |
| Subtypesa | |
| Informative N (%) | 757 (91.6%) |
| Luminal A | 229 (30.3%) |
| Luminal B | 263 (34.7%) |
| Luminal‐HER2 | 103 (13.6%) |
| HER2‐enriched | 78 (10.3%) |
| Triple‐negative | 84 (11.1%) |
a
Breast cancer subtypes defined by immunohistochemistry: luminal A (ER‐positive and/or PgR‐positive, HER2‐negative, Ki67 low); luminal B (ER‐positive and/or PgR‐positive, HER2‐negative, Ki67 high); luminal‐HER2 (ER‐positive and/or PgR‐positive, HER2‐positive); HER2‐enriched (ER‐negative, PgR‐negative, HER2‐positive); and triple‐negative (ER‐negative, PgR‐negative, and HER2‐negative).